Artificial intelligence is transforming drug development, with Eli Lilly leading the charge by launching its TuneLab platform to provide access to its proprietary knowledge. Partnering with Nvidia, the company aims to accelerate medicine discovery and production through a $1 billion supercomputer project. This move comes as the AI-powered drug discovery industry is projected to grow at an annual rate of 30% through 2034, reaching over $20 billion. With potential for partnerships and revenue growth, Eli Lilly’s foray into AI could reshape the pharmaceutical landscape. (Summary: Technology and pharmaceutical industries converge as AI revolutionizes drug development, with Eli Lilly at the forefront of innovation.)

Read more at Nasdaq: Forget AI Stocks: This Pharma Giant Is Using AI to Dominate Drug Discovery